PPHM Share Price

Open 0.58 Change Price %
High 0.60 1 Day 0.01 1.72
Low 0.58 1 Week 0.03 5.36
Close 0.59 1 Month -0.12 -16.90
Volume 771510 1 Year 0.19 47.50
52 Week High 0.77
52 Week Low 0.28
PPHM Important Levels
Resistance 2 0.61
Resistance 1 0.60
Pivot 0.59
Support 1 0.58
Support 2 0.57
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
AKRX 33.09 1.13%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
WRES 0.09 28.57%
More..
NASDAQ USA Top Gainers Stocks
PGRX 0.06 100.00%
SPIR 0.02 100.00%
LOCM 0.09 50.00%
RITT 0.03 50.00%
CLNT 4.50 30.81%
CALI 3.45 29.21%
WRES 0.09 28.57%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
ULTR 0.05 -37.50%
More..

Peregrine Pharmaceuticals Inc. (NASDAQ: PPHM)

PPHM Technical Analysis 3
As on 25th Apr 2017 PPHM Share Price closed @ 0.59 and we RECOMMEND Buy for LONG-TERM with Stoploss of 0.41 & Buy for SHORT-TERM with Stoploss of 0.59 we also expect STOCK to react on Following IMPORTANT LEVELS.
PPHM Target for April
1st Target up-side 0.76
2nd Target up-side 0.84
3rd Target up-side 0.92
1st Target down-side 0.54
2nd Target down-side 0.46
3rd Target down-side 0.38
PPHM Other Details
Segment EQ
Market Capital 78153800.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.peregrineinc.com
PPHM Address
PPHM
14282 Franklin Avenue
Tustin, CA 92780
United States
Phone: 714-508-6000
Fax: 714-838-5817
PPHM Latest News
Interactive Technical Analysis Chart Peregrine Pharmaceuticals Inc. ( PPHM NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Peregrine Pharmaceuticals Inc.
PPHM Business Profile
Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer. The Company's pipeline of investigational monoclonal antibodies is based on two technology platforms, including PS-targeting antibodies and DNA/histone-targeting antibodies. Bavituximab is the Company's therapeutic PS-targeting antibody, which has demonstrated therapeutic potential and represents a new approach to treating cancer. PGN650 is the Company's PS-targeting imaging agent that represents a potential new approach to imaging cancer. The Company is conducting three randomized Phase II trials for bavituximab in combination with standard chemotherapy for front and second-line non-small cell lung cancer and front-line pancreatic cancer. In addition to these company-sponsored trials for bavituximab, the Company has four investigator-sponsored trials looking at different treatment combinations and additional oncology indications.